You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):JMT601 1/2期臨牀試驗在美國完成首例患者給藥
格隆匯 12-14 16:45

格隆匯12月14日丨石藥集團(01093.HK)發佈公吿,公司附屬公司上海津曼特生物科技有限公司開發的首創在研藥物JMT601 (CPO107)的1/2 期臨牀試驗完成美國首例患者給藥。

該研究為一項在美國開展的多中心、首次人體、劑量遞增及劑量擴展的1/2期臨牀試驗,用以評估JMT601治療晚期非霍奇金氏淋巴瘤(NHL)患者的安全性、藥物代謝動力學及初步療效。

非霍奇金氏淋巴瘤(NHL)是由B淋巴細胞、T淋巴細胞或NK細胞引起的一組淋巴細胞增生性疾病。具有CD20表達的B細胞淋巴瘤佔美國NHL的大多數(約85%)。儘管大部分患者在診斷患有惰性NHL後可存活20年,但惡性淋巴瘤患者的預後較差,整體五年存活率約為60%。集團亦正於中國展開JMT601的1期臨牀試驗。該等研究的臨牀數據將引領JMT601 (CPO107)的全球臨牀開發。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account